Wake Forest School of Medicine.
Blood. 2021 May 27;137(21):2860-2861. doi: 10.1182/blood.2021011753.
In this issue of , Nair et al demonstrate that AAV-directed gene therapy using a new bioengineered FIX transgene provides higher FIX activity and superior hemostatic efficacy than other FIX variants and may allow for lower and potentially safer vector doses in future human clinical trials.
本期 ,奈尔等人证明,使用新型生物工程 FIX 转基因的 AAV 靶向基因治疗可提供比其他 FIX 变体更高的 FIX 活性和更好的止血效果,并且可能允许在未来的人类临床试验中使用更低、潜在更安全的载体剂量。